Literature DB >> 1512680

Rorschach changes following brief and short-term therapy.

J E Exner, A Andronikof-Sanglade.   

Abstract

Two groups of 35 patients each, one treated with brief therapy, averaging 14.2 sessions on a once per week basis, and the other group, treated with a short-term type of therapy, averaging 47 sessions on a once per week basis were administered the Rorschach and the Katz Adjustment Scales-Form S three times. The first administration took place before entering therapy. The brief therapy group was tested a second time at termination of treatment and again 8 to 12 months following termination. The short-term therapy group was tested the second time at therapy termination and the third time 10 to 12 months after termination. Each group reported substantially fewer symptoms at termination and continued to report about the same level of symptom reduction at the second retest. The Rorschach data seem to provide an ample basis from which to argue that considerable improvement occurred in the psychological organization and/or operations of both groups, and this appears to have some confirmation in the self-report data.

Entities:  

Mesh:

Year:  1992        PMID: 1512680     DOI: 10.1207/s15327752jpa5901_6

Source DB:  PubMed          Journal:  J Pers Assess        ISSN: 0022-3891


  3 in total

1.  Personality and psychiatric disorders in women affected by polycystic ovary syndrome.

Authors:  Elisabetta Scaruffi; Alessandra Gambineri; Stefania Cattaneo; Jenni Turra; Roberto Vettor; Roberto Mioni
Journal:  Front Endocrinol (Lausanne)       Date:  2014-11-12       Impact factor: 5.555

2.  Rorschach inkblot test and psychopathology among patients suffering from schizophrenia: A correlational study.

Authors:  Anwesha Mondal; Manish Kumar
Journal:  Ind Psychiatry J       Date:  2021-06-04

3.  Rorschach Evaluation of Personality and Emotional Characteristics in Adolescents With Migraine Versus Epilepsy and Controls.

Authors:  Laura Balottin; Stefania Mannarini; Daniela Candeloro; Alda Mita; Matteo Chiappedi; Umberto Balottin
Journal:  Front Neurol       Date:  2018-03-20       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.